Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of recombinant hepatitis E vaccine in adults with chronic hepatitis B
ChiCTR1900027077Phase 4Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Nov 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of HEV 239 in hepatitis E (HEV) (4 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoints: alanine aminotransferase, aspartate transaminase and 8 more. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on ChiCTR1900027077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027077.